Speaker Profile

M.D., M.P.H., Chief Medical Officer, Sidra Medicine

Ziyad M. Hijazi, MD, MPH is the Chief Medical Officer at Sidra Medicine, a specialist women’s and children’s healthcare facility in the State of Qatar. He was appointed to the role in April 2021. As CMO of Sidra Medicine, Prof. Hijazi is responsible for the overall management of the hospital’s clinical operations, upholding its clinical excellence and patient safety programs and ensuring that patients in Qatar receive the highest standard of medical care. Prof. Hijazi has nearly 40 years of experience in pediatric cardiology and has pioneered several ground-breaking surgical procedures in the field. He is an internationally recognized leader in the nonsurgical repair of congenital and structural heart defects and in the development of novel trans-catheter devices. Prof. Hijazi joined Sidra Medicine in 2014, during which time he established the hospital’s Department of Pediatrics and world-class Heart Center; staffed by some of the top pediatric specialists and healthcare professionals from across the globe. The Heart Center provides preventative, medical and surgical care for patients with congenital or acquired heart disease. Prof. Hijazi also successfully set up Sidra Medicine’s International Medical Office which has facilitated international patients to access to several specialist services, including cardiology, urology, plastics and neurosurgery among others. Over the course of three years, Sidra Medicine has saved the lives of hundreds of children from the MENA region, including India, Pakistan, North and South America. Pof. Hijazi is the Editor-in-Chief of the Journal of Structural Heart Disease. Has more than 350 manuscripts in peer reviewed journals and edited eight books. He is also the course director for the Pediatric Interventional Cardiac Symposium (PICS), which annually attracts more than 800 professionals from more than 60 countries.

 Session Abstract – PMWC 2022 Silicon Valley

Qatar Foundation’s Sidra Medicine is a leading regional research hospital and tertiary care facility for women and children, seeing nearly 200,000 patients in 2020. This session will explore the work at Sidra Medicine to take from bench to bedside the applications arising from newly analysed datasets of the Arab genome that will have benefits for patient care, pharmacogenomics and population health.